Androgen receptor (AR)
The androgen receptor (AR) is a member of the nuclear receptor superfamily of ligand-activated transcription factors, encoded by the AR gene on chromosome Xq11–12.
The androgen receptor (AR) is a member of the nuclear receptor superfamily of ligand-activated transcription factors, encoded by the AR gene on chromosome Xq11–12. It is built from an N-terminal domain carrying most of its transcriptional activity and a polymorphic polyglutamine tract, a central zinc-finger DNA-binding domain, and a C-terminal ligand-binding domain — a modular arrangement that matters clinically, since nearly every AR-directed drug engages one domain and can be escaped by altering another. Upon binding cognate androgens such as testosterone and its more potent metabolite dihydrotestosterone (DHT), AR undergoes a conformational change, dissociates from cytoplasmic chaperone complexes, and translocates to the nucleus, where it binds androgen response elements (AREs) in target gene promoters and enhancers to drive transcriptional programs governing cell proliferation, survival, and differentiation. Loss-of-function mutations cause androgen insensitivity syndrome, and expansion of the polyglutamine tract causes spinal and bulbar muscular atrophy, so both too little AR activity and an aberrant receptor produce distinct disease. Beyond its classical role in male sexual development and the prostate, AR exerts context-dependent effects in hair follicles, the central nervous system, immune cells, and a variety of epithelial cancers.
AR is best recognized as the central oncogenic driver in prostate cancer, where sustained androgen signaling fuels tumor growth even under systemic androgen deprivation; prostate cancer that progresses despite castrate androgen levels or androgen-deprivation therapy is termed castration-resistant prostate cancer (CRPC). CRPC does not proceed by abandoning the receptor but by restoring its signal: AR amplification and overexpression that respond to residual ligand, gain-of-function mutations that let antagonists or adrenal steroids act as agonists, intratumoral androgen synthesis, constitutively active splice variants — notably AR-V7, which lacks the ligand-binding domain altogether and so is indifferent to drugs that target it — and cistrome reprogramming that redirects AR to non-canonical transcriptional networks.
Therapy follows the same logic in reverse, attacking ligand supply and receptor function at separate points: gonadal suppression, abiraterone blocking the CYP17A1 step of androgen synthesis including within the tumor, and receptor antagonists such as enzalutamide that prevent nuclear translocation and DNA binding. Because escape routes converge on restoring AR output, degraders that remove the protein and agents directed at the N-terminal domain are being pursued to defeat variants no ligand-binding-site drug can reach. Prolonged suppression also selects for tumors that stop depending on AR entirely, emerging as neuroendocrine prostate cancer. Emerging evidence implicates AR in tumor immunology, metabolic regulation, and conditions such as androgenetic alopecia (AGA), broadening therapeutic interest well beyond prostate cancer.
Where the papers sit
8 papers from the last 6 months study Androgen receptor (AR) directly · updated from PubMed 15 Nov 2026
Study type 1 clinical trial · 2 observational · 3 preclinical · 2 unclassified
Themes 3 themes
-
AR-Directed Therapeutic Strategies
AR-directed therapy is moving beyond conventional antagonism toward degraders, transcriptional control and context-specific agonism. BMS-986365 combines ligand-directed degradation with antagonism, while other work links AR transcriptional repression of VCP to stronger oncolytic-immunotherapy effects in hepatocellular carcinoma. AR agonism is being explored in estrogen receptor-positive metastatic breast cancer, contrasting with antagonists designed for topical use and improved safety. The common goal is to exploit AR biology differently across diseases, but therapeutic context and selectivity remain open questions.
4 papers · 50%
-
PSMA Imaging in Prostate Cancer
PSMA imaging is being paired with androgen-directed treatment to improve staging and response interpretation in metastatic prostate cancer. Darolutamide is under study for its effect on PSMA flare, which may mimic progression on molecular imaging. Bavdegalutamide (ARV-110) is being combined with abiraterone in a phase 1b trial. The key open issue is distinguishing treatment-related flare from true disease change while defining imaging-guided clinical benefit.
2 papers · 25%
-
AR in Neoadjuvant Breast Cancer
AR expression is being evaluated as a prognostic marker in breast cancer treated with neoadjuvant chemotherapy. Associations with tumor grade and pathological complete response recur, but the broader conclusion is prognostic rather than predictive. AR status therefore does not yet identify who will benefit from chemotherapy. The unresolved question is whether subtype-specific AR biology can improve treatment selection beyond standard clinicopathologic factors.
2 papers · 25%
Papers
The 8 papers from the last 6 months that study Androgen receptor (AR) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
AR-Directed Therapeutic Strategies (4)
- Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365. Journal of medicinal chemistry · 10 Jul 2026 PMID 42430428
- Novel Dual Soft Drug Strategy Enables Development of Topical Androgen Receptor Antagonists with Enhanced Efficacy and Optimized Safety for Androgenetic Alopecia. Journal of medicinal chemistry · 8 Jul 2026 PMID 42418259
- Targeting androgen receptor transcriptionally represses VCP and enhances the efficacy of oncolytic-immunotherapy in hepatocellular carcinoma. Pharmacological research · 27 Jun 2026 PMID 42364832
- Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer. NPJ breast cancer · 17 Jun 2026 PMID 42310300
PSMA Imaging in Prostate Cancer (2)
- The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol. BMJ open · 18 Jun 2026 PMID 42315278
- Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 2 Jun 2026 PMID 42227954
AR in Neoadjuvant Breast Cancer (2)
- Prognostic significance of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy: A retrospective cohort study. Medicine · 15 Aug 2026 PMID 42601757
- Prognostic but not predictive: the clinical implications of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy. Future oncology (London, England) · 30 Jun 2026 PMID 42376794
By study type
Clinical trials (1)
- The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol. BMJ open · 18 Jun 2026 PMID 42315278
Observational studies and case reports (2)
- Prognostic significance of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy: A retrospective cohort study. Medicine · 15 Aug 2026 PMID 42601757
- Prognostic but not predictive: the clinical implications of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy. Future oncology (London, England) · 30 Jun 2026 PMID 42376794
Preclinical: animal, cell and lab studies (3)
- Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365. Journal of medicinal chemistry · 10 Jul 2026 PMID 42430428
- Novel Dual Soft Drug Strategy Enables Development of Topical Androgen Receptor Antagonists with Enhanced Efficacy and Optimized Safety for Androgenetic Alopecia. Journal of medicinal chemistry · 8 Jul 2026 PMID 42418259
- Targeting androgen receptor transcriptionally represses VCP and enhances the efficacy of oncolytic-immunotherapy in hepatocellular carcinoma. Pharmacological research · 27 Jun 2026 PMID 42364832
Unclassified: not yet indexed with MeSH (2)
- Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer. NPJ breast cancer · 17 Jun 2026 PMID 42310300
- Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 2 Jun 2026 PMID 42227954
Written from 8 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-08-26 by GPT. Corrections: 2026-08-08 by GPT. Drafted by language models from published abstracts; not medical advice.